CN102203075B - 二环激酶抑制剂 - Google Patents
二环激酶抑制剂 Download PDFInfo
- Publication number
- CN102203075B CN102203075B CN200980143219.4A CN200980143219A CN102203075B CN 102203075 B CN102203075 B CN 102203075B CN 200980143219 A CN200980143219 A CN 200980143219A CN 102203075 B CN102203075 B CN 102203075B
- Authority
- CN
- China
- Prior art keywords
- amino
- pyridine
- amine
- naphthyridines
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NGJDBEPBSXAKJA-UHFFFAOYSA-N C(c1ccccc1)Oc1c(cc(cc2)-c3nc(-c4ncc[s]4)ccc3)c2ncc1 Chemical compound C(c1ccccc1)Oc1c(cc(cc2)-c3nc(-c4ncc[s]4)ccc3)c2ncc1 NGJDBEPBSXAKJA-UHFFFAOYSA-N 0.000 description 1
- IGAHBXXNANHMSF-UHFFFAOYSA-N CC(C)(C)OC(NC(CCC1)CN1c1c(cc(-c2nc(Cl)ccc2N)nc2)c2ncc1)=O Chemical compound CC(C)(C)OC(NC(CCC1)CN1c1c(cc(-c2nc(Cl)ccc2N)nc2)c2ncc1)=O IGAHBXXNANHMSF-UHFFFAOYSA-N 0.000 description 1
- UZXOFQZDRJVAPO-HNNXBMFYSA-N CC(C)(C)OC(N[C@@H](CCC1)CN1c1c(cc(B2OC(C)(C)C(C)(C)O2)nc2)c2ncc1F)=O Chemical compound CC(C)(C)OC(N[C@@H](CCC1)CN1c1c(cc(B2OC(C)(C)C(C)(C)O2)nc2)c2ncc1F)=O UZXOFQZDRJVAPO-HNNXBMFYSA-N 0.000 description 1
- OBQAWISNFFAHCG-UHFFFAOYSA-N CCNC(c(cc1)cc(-c(nc2-c(ncc3ncc4)cc3c4N(CCC3)CC3N)ccc2N)c1F)=O Chemical compound CCNC(c(cc1)cc(-c(nc2-c(ncc3ncc4)cc3c4N(CCC3)CC3N)ccc2N)c1F)=O OBQAWISNFFAHCG-UHFFFAOYSA-N 0.000 description 1
- VTRWDSJJRKZKJO-UHFFFAOYSA-N Cc1cc(-c2c(cc(nc3)Cl)c3ncc2)cc(N)n1 Chemical compound Cc1cc(-c2c(cc(nc3)Cl)c3ncc2)cc(N)n1 VTRWDSJJRKZKJO-UHFFFAOYSA-N 0.000 description 1
- ZSKQBENZWMTYDG-UHFFFAOYSA-N O=S(C(F)(F)F)(Oc1c(cc(cc2)-c3nc(-c4ncc[s]4)ccc3)c2ncc1)=O Chemical compound O=S(C(F)(F)F)(Oc1c(cc(cc2)-c3nc(-c4ncc[s]4)ccc3)c2ncc1)=O ZSKQBENZWMTYDG-UHFFFAOYSA-N 0.000 description 1
- KLNIWHBTRHRYBM-UHFFFAOYSA-N O=S(C(F)(F)F)(Oc1c(cc(nc2)Cl)c2ncc1)=O Chemical compound O=S(C(F)(F)F)(Oc1c(cc(nc2)Cl)c2ncc1)=O KLNIWHBTRHRYBM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9366908P | 2008-09-02 | 2008-09-02 | |
| US61/093,669 | 2008-09-02 | ||
| PCT/EP2009/061182 WO2010026121A1 (en) | 2008-09-02 | 2009-08-31 | Bicyclic kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102203075A CN102203075A (zh) | 2011-09-28 |
| CN102203075B true CN102203075B (zh) | 2014-09-10 |
Family
ID=41211220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980143219.4A Expired - Fee Related CN102203075B (zh) | 2008-09-02 | 2009-08-31 | 二环激酶抑制剂 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8735424B2 (https=) |
| EP (1) | EP2342190A1 (https=) |
| JP (1) | JP5564045B2 (https=) |
| KR (1) | KR20110058866A (https=) |
| CN (1) | CN102203075B (https=) |
| AU (1) | AU2009289316A1 (https=) |
| BR (1) | BRPI0918496A2 (https=) |
| CA (1) | CA2735779A1 (https=) |
| EA (1) | EA201100426A1 (https=) |
| MX (1) | MX2011002367A (https=) |
| WO (1) | WO2010026121A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| SI2432472T1 (sl) | 2009-05-22 | 2019-11-29 | Incyte Holdings Corp | 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| EP3812387A1 (en) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| CA2897279C (en) | 2013-01-23 | 2020-12-29 | Astrazeneca Ab | Aminopyrazine derivatives and pharmaceutical compositions thereof for use in the treatment of cancer |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| CL2015001657S1 (es) | 2014-12-15 | 2016-09-02 | Jjgc Indústria E Comércio De Materiais Dentários S A | Configuracion aplicada a implante oseo. |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| US10376504B2 (en) | 2015-07-29 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Substituted quinolinones as PDE9 inhibitors |
| WO2017019724A1 (en) | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone pde9 inhibitors |
| WO2017019726A1 (en) | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Oxy-cyanoquinolinone pde9 inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| PT3889145T (pt) * | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| IL264178B2 (en) | 2016-07-14 | 2024-05-01 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| CN105974036A (zh) * | 2016-07-31 | 2016-09-28 | 合肥远志医药科技开发有限公司 | 一种氨基吡啶异构体的检测方法 |
| EP4198031A1 (en) | 2016-08-08 | 2023-06-21 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| JP2021521170A (ja) | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤 |
| CN112823158B (zh) * | 2018-08-24 | 2023-08-15 | 拜耳股份有限公司 | 制备2-[(3r)-3-甲基吗啉-4-基]-4-(1-甲基-1h-吡唑-5-基)-8-(1h-吡唑-5-基)-1,7-二氮杂萘的方法 |
| KR20260008165A (ko) | 2019-02-12 | 2026-01-15 | 스미토모 파마 아메리카, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CA3191084A1 (en) | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
| WO2022090101A1 (en) | 2020-10-26 | 2022-05-05 | Boehringer Ingelheim International Gmbh | Process for synthesis of 2,4-dichloro-5-aminopyrimidine |
| EP4277626A4 (en) * | 2021-01-14 | 2024-12-11 | Georgetown University | USP13 INHIBITORS AND METHODS OF USE THEREOF |
| CN113648294B (zh) * | 2021-08-26 | 2024-01-23 | 山东领海生物科技有限公司 | β-双磺酰亚胺取代酮类化合物在治疗癌症中的应用 |
| CN120302975A (zh) | 2022-10-31 | 2025-07-11 | 住友制药美国公司 | 治疗骨髓增生性肿瘤的pim1抑制剂 |
| WO2024186839A1 (en) * | 2023-03-05 | 2024-09-12 | University Of Vermont And State Agricultural College | Bicyclic aryl sulfonamides, sulfones, and sulfonate esters as anti-parasitic agents |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017500A (en) * | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| WO2005120509A1 (en) * | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| CN1856475A (zh) * | 2003-09-23 | 2006-11-01 | 默克公司 | 异喹啉钾通道抑制剂 |
| WO2006135993A1 (en) * | 2005-06-24 | 2006-12-28 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c. |
| WO2008009078A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| WO2008144464A1 (en) * | 2007-05-18 | 2008-11-27 | Smithkline Beecham Corporation | Quinoline derivatives as p13 kinase inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815617A1 (de) * | 1988-05-07 | 1989-11-16 | Bayer Ag | 4-aza-1,10-phenanthrolin-derivate, verfahren zu ihrer herstellung sowie ihre verwendung in schaedlingsbekaempfungsmitteln |
| DE4011105A1 (de) * | 1990-04-06 | 1991-10-10 | Bayer Ag | Neue 4-chinolyl-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| US5204472A (en) * | 1990-04-06 | 1993-04-20 | Bayer Aktiengesellschaft | Quinoline and isoquinoline intermediates |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| AR007857A1 (es) * | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9708917D0 (en) * | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
| EP1539754A4 (en) * | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | BENZIMIDAZOCHINOLINONE AND ITS USE |
| JP4690043B2 (ja) * | 2002-10-04 | 2011-06-01 | プラナ バイオテクノロジー リミティッド | 神経に対し活性な化合物 |
| JP2006219453A (ja) | 2005-02-14 | 2006-08-24 | Tokyo Univ Of Pharmacy & Life Science | キノリン環を母核とする金属識別型二波長性蛍光分子 |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| PL2344474T3 (pl) * | 2008-09-02 | 2016-03-31 | Novartis Ag | Pochodne pikolinamidu jako inhibitory kinaz |
-
2009
- 2009-08-31 JP JP2011524403A patent/JP5564045B2/ja not_active Expired - Fee Related
- 2009-08-31 MX MX2011002367A patent/MX2011002367A/es not_active Application Discontinuation
- 2009-08-31 BR BRPI0918496A patent/BRPI0918496A2/pt not_active IP Right Cessation
- 2009-08-31 AU AU2009289316A patent/AU2009289316A1/en not_active Abandoned
- 2009-08-31 WO PCT/EP2009/061182 patent/WO2010026121A1/en not_active Ceased
- 2009-08-31 CN CN200980143219.4A patent/CN102203075B/zh not_active Expired - Fee Related
- 2009-08-31 US US13/060,971 patent/US8735424B2/en active Active
- 2009-08-31 CA CA2735779A patent/CA2735779A1/en not_active Abandoned
- 2009-08-31 EA EA201100426A patent/EA201100426A1/ru unknown
- 2009-08-31 EP EP09782373A patent/EP2342190A1/en not_active Withdrawn
- 2009-08-31 KR KR1020117007560A patent/KR20110058866A/ko not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017500A (en) * | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| CN1856475A (zh) * | 2003-09-23 | 2006-11-01 | 默克公司 | 异喹啉钾通道抑制剂 |
| WO2005120509A1 (en) * | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| WO2006135993A1 (en) * | 2005-06-24 | 2006-12-28 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c. |
| WO2008009078A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| WO2008144464A1 (en) * | 2007-05-18 | 2008-11-27 | Smithkline Beecham Corporation | Quinoline derivatives as p13 kinase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| "Synthesis of ABC Analogues of the Antitumour Antibiotic Streptonigrin";Marc Kimber, et al.;《Tetrahedron》;20001231;第56卷;第3575-3581页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201100426A1 (ru) | 2011-10-31 |
| US8735424B2 (en) | 2014-05-27 |
| KR20110058866A (ko) | 2011-06-01 |
| JP5564045B2 (ja) | 2014-07-30 |
| EP2342190A1 (en) | 2011-07-13 |
| WO2010026121A1 (en) | 2010-03-11 |
| MX2011002367A (es) | 2011-04-04 |
| AU2009289316A1 (en) | 2010-03-11 |
| US20110195980A1 (en) | 2011-08-11 |
| JP2012501312A (ja) | 2012-01-19 |
| CN102203075A (zh) | 2011-09-28 |
| BRPI0918496A2 (pt) | 2019-09-24 |
| CA2735779A1 (en) | 2010-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102203075B (zh) | 二环激酶抑制剂 | |
| CN102197032B (zh) | 杂环pim-激酶抑制剂 | |
| CN101679266B (zh) | Pim激酶抑制剂及其应用方法 | |
| JP5412448B2 (ja) | Ｐｉｍキナーゼ阻害剤およびその使用方法 | |
| CA3170321A1 (en) | Novel prmt5 inhibitors | |
| CN104520290B (zh) | 酰氨基螺环酰胺和磺酰胺衍生物 | |
| US20120225061A1 (en) | Tetrasubstituted cyclohexyl compounds as kinase inhibitors | |
| US20120202851A1 (en) | Pim kinase inhibitors and methods of their use | |
| AU2017208555B2 (en) | New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | |
| CN113316576A (zh) | 用于治疗癌症的作为HPK1抑制剂的2,3-二氢-1H-吡咯并[3,4-c]吡啶-1-酮衍生物 | |
| WO2014033631A1 (en) | N-(3-pyridyl) biarylamides as kinase inhibitors | |
| IL211291A (en) | Picolinamide Compounds, Pharmaceuticals Containing Them, and Their Use in the Preparation of Cancer Drugs | |
| WO2014099880A1 (en) | Aryl-substituted fused bicyclic pyridazine compounds | |
| WO2014033630A1 (en) | Novel aminothiazole carboxamides as kinase inhibitors | |
| JP2019524646A (ja) | Ｎｉｋ阻害剤としてのシアノインドリン誘導体 | |
| WO2022017434A1 (zh) | 一类具有激酶抑制活性的化合物 | |
| US12552785B2 (en) | Pyrazolo[1,5-α]pyridine derivative, preparation method therefor, and composition and use thereof | |
| JP2009073743A (ja) | 新規な縮合環式ピリミジン化合物又はその塩、及びその医薬組成物 | |
| AU2012200132A1 (en) | "Picolinamide derivatives as kinase inhibitors" | |
| EP4036086A1 (en) | Heterocyclic derivative and use thereof | |
| HK40053093A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Basel Applicant after: Novartis Ag Address before: Basel Applicant before: Novartis AG |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140910 Termination date: 20150831 |
|
| EXPY | Termination of patent right or utility model |